InTouch

January / February 2026

ISPE Announces New International Board of Directors

ISPE

ISPE elected a new 2025–2026 International Board of Directors, which is responsible for the governance and strategic direction of ISPE.

The election was run by an independent third party, which provided ISPE with the final audited results. Board members assumed their elected positions at the 2025 ISPE Annual Meeting & Expo, held in Charlotte, NC, US, and virtually from 26–29 October. The following pharmaceutical industry leaders have been elected to positions on the 2025–2026 ISPE International Board of Directors.

Executive Committee

Elected to a Second Term

Liz Dooley

Senior Director, Global Engineering & Technology

Johnson & Johnson

New Directors

Jose Caraballo-Oramas

Vice President, Quality

Kite, a Gilead Company

Victor Cruz

Sr. VP of Corporate Engineering and Global Health, Safety and Environmental

Eli LIlly & Company - Corporate Engineering

Francesco Intoccia

SVP Global Engineering, EHS & Sustainability

GSK

Board Members Continuing a Term in 2025-2026

The following individuals will be continuing a two-year term in 2025-2026.

Norman Goldschmidt

President

Genesis AEC

James Grunwald

Senior Vice President US Business Development

Arcadis

Shanshan Liu

Technical Director

No Deviation Pte Ltd

Vivien Santillan

Regional Director, Asia

Novatek International

InTouch

Meet the ISPE Staff: Gabriela Kantor

1 January 2026

In each issue of Pharmaceutical Engineering^®, we introduce a member of the ISPE staff who provides ISPE members with key information and services. Meet Gabriela Kantor, Technical Editor, Publications team.

InTouch

Digital Manufacturing and Supply: An ISPE D/A/CH Workshop

1 January 2026

The 2025 ISPE D/A/CH workshop on “Pharma’s Journey to Digital Manufacturing and Supply” united pharma leaders, technology experts, and regulatory authorities for three days of intense exchange on the digital transformation of our industry.

InTouch

New ISPE Guide: ATMPs – Validation Methods and Controls Throughout the Cell and Gene Therapy Lifecycle

1 January 2026

Advanced therapy medicinal products (ATMPs) represent a revolutionary frontier in medicine, offering life-changing treatments for conditions previously deemed incurable. However, the intricate nature of these therapies, from their unique raw materials to complex manufacturing and logistics, presents significant challenges and inherent risks, including how to best develop validation methods and...